James Crowe Jr. Archives
Potent HIV antibodies suggest new vaccine development approach
Apr. 7, 2016—It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks.
Vanderbilt researchers identify potential antibody treatment for H7 avian flu
Mar. 7, 2016—Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.
Antibodies may be ‘silver bullet’ for Ebola viruses
Jan. 21, 2016—There may be a “silver bullet” for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years.
Caucus explores crucial role of NIH research funding
Dec. 3, 2015—James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, and Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), recently participated in a U.S. Senate National Institutes of Health (NIH) caucus briefing held in Washington, D.C., by Senate NIH caucus co-chairs Sens. Lindsey Graham (R-SC) and Dick Durbin (D-IL).
Two Ebola Survivors’ Blood Could Help Vanderbilt Researchers Find A Treatment
Oct. 19, 2015—Vanderbilt researchers could be one step closer to finding a way to fight the deadly Ebola virus – thanks to two Ebola victims from Nigeria, who faced death and survived. Vanderbilt researchers developed a unique method of isolating potent Ebola-fighting antibodies from survivors’ blood and they believe these newest potent antibody samples are an important...
Survivors of Ebola outbreak take part in VUMC vaccine study
Sep. 24, 2015—Two survivors of a 2014 Ebola outbreak in Nigeria visited Vanderbilt University Medical Center last week to share their experiences and participate in a study aimed at finding ways to treat the often-fatal infection.
Ebola symposium to feature Nigerian physicians
Sep. 10, 2015—Three Nigerian physicians who survived Ebola virus disease in July 2014 after coming in direct contact with an Ebola-infected patient will speak at Vanderbilt University Medical Center next Wednesday, Sept. 16.
How to trick a wily virus
Jul. 24, 2015—Vanderbilt investigators have discovered how human antibodies induced during testing of an experimental “bird flu” vaccine kill the virus.
Study could lead to vaccine for mosquito-borne dengue virus
Jul. 9, 2015—Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.
Vanderbilt researchers develop potential treatment to fight mosquito-borne chikungunya virus
Jul. 8, 2015—In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States.
‘Redesigned’ antibodies may control HIV: study
May. 21, 2015—With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.
VU lands $9 million NIH grant to design better flu vaccines
May. 15, 2015—Vanderbilt University researchers have received a five-year, $9 million grant from the National Institutes of Health (NIH) to design more effective flu vaccines and novel antibody therapies.
